Stephens upgraded Exelixis (EXEL) to Overweight from Equal Weight with a price target of $60, up from $29.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- More data needed to determine Exelixis’ competitive positioning, says BofA
- Exelixis price target raised to $55 from $43 at Truist
- Exelixis price target raised to $50 from $47 at Citizens JMP
- Exelixis: Promising Clinical Trial Success and Strong Future Prospects Drive Buy Rating
- Exelixis announces ‘positive’ results from STELLAR-303 phase 3 trial